Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1
Fundamental & Clinical Pharmacology · 2025
DOI: 10.1111/fcp.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Jing Bai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Relaxin, Endothelial Cells, Monocytes, Early Growth Response Protein 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Renmin Hospital of Wuhan University.
Abstract (Originalsprache)
Background
An overproduction of oxidized low‐density lipoprotein (ox‐LDL) can lead to vascular endothelial dysfunction. Relaxin‐2, a novel peptide hormone, exhibits various biological functions within the cardiovascular system. However, the effects of Relaxin‐2 in atherosclerosis (AS) are underreported.
Objectives
We aimed to investigate the regulatory role of Relaxin‐2 in the endothelial function of human aortic endothelial cells (HAECs) upon ox‐LDL stimulation.
Methods
HAECs were stimulated with ox‐LDL (100 mg/l) and rhRelaxin‐2 (25, 50 nM) for 24 h. Multiple techniques, including real‐time PCR, Western blot analysis, ELISA, and Calcein AM staining, were applied.
Results
Treatment with human recombinant (rh) Relaxin‐2 decreased lectin‐like ox‐LDL receptor 1 (LOX‐1), a primary receptor for ox‐LDL, in HAECs. rhRelaxin‐2 also reduced the ox‐LDL‐induced expression of pro‐inflammatory mediators such as interleukin 6 (IL‐6), tumor necrosis factor‐α (TNF‐α), and monocyte chemoattractant protein‐1 (MCP‐1). Additionally, we observed increased expression of cyclooxygenase‐2 (COX‐2), prostaglandin E2 (PGE2), and high mobility group protein B1 (HMGB‐1) in ox‐LDL‐challenged HAECs, which was diminished by rhRelaxin‐2. Significantly, the heightened expression of intercellular cell adhesion molecule‐1 (ICAM‐1) and E‐selectin in ox‐LDL‐stimulated HAECs was mitigated by rhRelaxin‐2. Consequently, rhRelaxin‐2 alleviated the attachment of THP‐1 cells to HAECs in a dose‐dependent manner. Mechanistically, we found that rhRelaxin‐2 inhibited the expression of Egr‐1, a central mediator of endothelial inflammation. Furthermore, overexpression of Egr‐1 was found to negate the beneficial effects of rhRelaxin‐2, suggesting that these effects are mediated by the suppression of Egr‐1.
Conclusion
Our findings propose a novel therapeutic approach with rhRelaxin‐2 for patients with atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Ultrasound, Wuhan Prevention and Treatment Center for Occupational Diseases, Wuhan, China.
ORCID-Profile: Jing Bai
Förderung
- Renmin Hospital of Wuhan University
Zitieren
APA
Bai, J., & Zhou, H. (2025). Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70007
Vancouver
Bai J, Zhou H. Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70007
BibTeX
@article{Bai2025,
author = {Bai, Jing and Zhou, Hui},
title = {Relaxin‐2 mitigates the interaction between monocytes and endothelial cells by suppressing Egr‐1},
journal = {Fundamental & Clinical Pharmacology},
year = {2025},
doi = {10.1111/fcp.70007}
}
EUVIMED